Biomarin Pharmaceutical Inc (BMRN)
Days of sales outstanding (DSO)
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Receivables turnover | 4.28 | 3.51 | 3.71 | 3.83 | 3.74 | 3.95 | 3.58 | 3.55 | 4.46 | 4.76 | 4.08 | 4.35 | 4.89 | 4.88 | 4.46 | 4.58 | 4.07 | 4.43 | 4.76 | 4.47 | |
| DSO | days | 85.19 | 103.89 | 98.42 | 95.20 | 97.47 | 92.40 | 101.95 | 102.79 | 81.76 | 76.60 | 89.45 | 83.89 | 74.58 | 74.80 | 81.89 | 79.64 | 89.78 | 82.46 | 76.73 | 81.61 |
December 31, 2024 calculation
DSO = 365 ÷ Receivables turnover
= 365 ÷ 4.28
= 85.19
Days Sales Outstanding (DSO) is a measure of how long it takes a company to collect payment after making a sale. Analyzing Biomarin Pharmaceutical Inc's DSO from March 31, 2020, to December 31, 2024, reveals fluctuations in the efficiency of the company's accounts receivable management.
The DSO started at 81.61 days on March 31, 2020, and showed variations over the period, reaching a peak of 103.89 days on September 30, 2024. This increase indicates that Biomarin Pharmaceutical Inc took longer to collect payment from customers, potentially impacting cash flow and liquidity. Conversely, the lowest DSO was recorded at 74.58 days on December 31, 2021, suggesting an improvement in receivables management efficiency.
Overall, Biomarin Pharmaceutical Inc experienced fluctuations in its DSO over the period, indicating changes in its credit policies, customer payment behaviors, or collection processes. A rising trend in DSO should prompt further investigation into the company's credit risk and collection practices to ensure timely and efficient cash flow management.
Peer comparison
Dec 31, 2024